期刊文献+

广东台山HIV携带者 艾滋病患者血培养阳性病原菌种类及药敏分析 被引量:1

Drug sensitivity and positive pathogenic bacteria types of blood culture for HIV carriers and AIDS patients in Taishan of Guangdong province
下载PDF
导出
摘要 目的了解2009年1月至2011年10月广东台山人类免疫缺陷病毒(HIV)携带者和艾滋病(AIDS)患者血培养阳性病原菌种类及耐药情况,认真执行血培养的标准化操作。方法血培养用美国BD9050全自动血培养仪、法国生物梅里埃公司血培养双相瓶,鉴定、药敏用法国生物梅里埃公司ATB Expression自动细菌鉴定仪。结果 2009年1月至2011年10月46例血培养阳性的HIV携带者和AIDS患者病原菌种类包括22株革兰阳性球菌、10株革兰阴性杆菌、14株真菌,分别占47.8%、21.7%、30.5%;革兰阳性球菌、革兰阴性杆菌、真菌对抗菌药物基本敏感。结论 HIV携带者血培养阳性病原菌主要是金黄色葡萄球菌,AIDS患者血培养阳性病原菌主要是马尓尼菲青霉菌。 Objective To understand drug sensitivity and positive pathogenic bacteria types of blood culture for HIV carriers and AIDS patients in Taishan of Guangdong province from January 2009 to October 2011,also to carry out standard operation of blood culture.Methods Blood culture was processed by United States BD9050 automated blood culture instrument and French bioMerieux biphasic blood culture bottles.Identification and drug sensitivity were tested by French bioMerieux MUI ATB Expression automatic bacteria identification system.Results From January 2009 to October 2011,in 46 cases of blood culture of positive pathogens in HIV carriers and AIDS patients,22(47.8%) were Gram-positive cocci,10(21.7%)were Gram-negative bacilli,14(30.5%)were fungi.Gram-positive cocci,gram-negative bacteria and fungi were sensitive to antimicrobial drugs.Conclusion Staphylococcus aureus is dominant in positive pathogens of blood culture for HIV carriers.Penicillium marneffei is dominant in positive pathogens of blood culture for AIDS patients.
出处 《检验医学与临床》 CAS 2012年第6期671-672,675,共3页 Laboratory Medicine and Clinic
关键词 人类免疫缺陷病毒 艾滋病 血培养阳性 病原菌 耐药性 human immunodeficiency virus AIDS positive blood cultures pathogenic bacteria drug resistance
  • 相关文献

参考文献4

二级参考文献20

  • 1夏愔愔,詹思延.国内抗结核药物不良反应发生率的综合分析[J].中华结核和呼吸杂志,2007,30(6):419-423. 被引量:208
  • 2赵勇华,于建武,李树臣.拉米夫定预防乙型肝炎病毒携带者抗结核治疗致肝损伤的临床疗效[J].中华传染病杂志,2007,25(5):303-306. 被引量:4
  • 3Hung CC,Chen MY,Hsiao CF,et al.Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.AIDS,2003,17:2615-2622.
  • 4Friedland G,Khoo S,Jack C,et al.Administration of efavirenz (600mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.J Antimicrob Chemother,2006,58:1299-1302.
  • 5Manosuthi W,Kiertiburanakul S,Phoorisri T,et al.Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy.J Infect,2006,53:357-363.
  • 6Harries A,Maher D,Graham S.TB/HIV:A Clinical Manual.2nd ed.Geneva:World Health Organization,2004.
  • 7中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册(第二版)[EB/OL].(2008-04-08).http://www.chinaaids.cn/n16/n1657/n32880.files/n32881.pdf.
  • 8Saukkonen JJ,Cohn DL,Jasmer RM,et al.An official ATS statement:hepatotoxicity of antituberculosis therapy.Am J Respir Crit Care Med,2006,174:935-952.
  • 9Ho CC,Chen YC,Hu FC,et al.Safety of fluoroquinolone use in patients with hepatotoxicity induced by antituberculosis regimens.Clin Infect Dis,2009,48:1526-1533.
  • 10Gerberding JL,Popovic T,Stephens JW,et al.Guidelines for prevention and treatment of opportunistic infections in HIV-1-infected adults and adolescents[EB/OL].(2009-03-25).http://www.cdc.gov/mmwr/pdf/rr/rr58e324.pdf.

共引文献13

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部